DPP4 and non-small cell lung carcinoma: Taken together, our data suggest that the ability of API to inhibit cell invasiveness might be attributable to its capacity to suppress CD26 expression followed by inhibiting the EMT, and API has potential value in clinical applications for advanced NSCLC.